Evaluating the effects of lebrikizumab on well-being in adults with moderate-to-severe atopic dermatitis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study assesses how lebrikizumab treatment impacts the health-related well-being and skin symptoms of adults suffering from moderate-to-severe atopic dermatitis in real-world clinical settings across Europe. It utilizes the validated WHO-5 Well-being Index to measure overall well-being, treatment satisfaction, and the long-term effects of the medication on various aspects of life, including disease control and quality of life. Participants are adults who have been prescribed lebrikizumab as part of their routine care for atopic dermatitis.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult (greater than or equal to \[\>=\] 18 years) male or female participants with diagnosis of moderate-to-severe Atopic dermatitis.
* Adult participants prescribed lebrikizumab as part of routine/usual care to manage their moderate-to severe Atopic dermatitis.
* Willingness and ability to participate in the study; participants must give their written consent to participate.

Exclusion Criteria:

* Hypersensitivity to the active substances or to any of the excipients of lebrikizumab (Ebglyss®).
* Participants with pre-existing helminth infections. These participants should be treated for helminth infection before starting lebrikizumab therapy.
* Concomitant use of live and live attenuated vaccines.
* Pregnant women, except when the potential benefit justifies the potential risk.
* Participants included in a clinical trial at baseline or at any time during the planned study period.
* Participants unable to comply with the requirements of the study or who, in the opinion of the study physician, should not participate in the study.
* Participants for whom medical chart is inaccessible to physicians to complete baseline data collection.

Where it's running

• Aarhus University Hospital
  Aarhus, Denmark, Denmark Recruiting

Study contacts

• Study coordinator: Èric Massana
• Email: eric.massana@almirall.com
• Phone: 0034 932 913 986

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• How lebrikizumab affects the skin microbiome and mycobiome in adults with atopic dermatitis

  This study looks at whether lebrikizumab changes the skin bacteria, fungi, and specifically Staphylococcus species, in adults with moderate-to-severe atopic dermatitis.

  Recruiting University Hospital Bispebjerg and Frederiksberg · Copenhagen · NCT07807228

• Digital mindfulness app for teens with eczema

  Teens with moderate to severe eczema try a digital mindfulness app to see if it helps control symptoms and improve quality of life.

  Recruiting at 2 sites Weill Medical College of Cornell University · New York, New York and 1 other locations · NCT07746427

• Camoteskimab in adults with moderate-to-severe atopic dermatitis

  This trial tests different doses of camoteskimab versus placebo to see if it helps adults with moderate-to-severe atopic dermatitis who have not fully responded to standard treatments.

  Recruiting at 31 sites Phase 2 Apollo Therapeutics Ltd · Birmingham, Alabama and 84 other locations · NCT07599813

• Low-sodium diet and salt tablets to see if eczema improves

  This study tests whether a low-sodium diet can lessen eczema symptoms in adults with atopic dermatitis, using a cross-over design with sodium tablets and placebo to see if salt intake changes skin sodium and severity.

  Recruiting at 2 sites Phase 4 University of California, San Francisco · San Francisco, California and 1 other locations · NCT07447063

• Soquelitinib for adults with moderate to severe atopic dermatitis

  This 12-week test gives adults with moderate to severe atopic dermatitis daily soquelitinib or a placebo to see if their skin and itch improve and to track side effects.

  Recruiting Phase 2 Corvus Pharmaceuticals, Inc. · South San Francisco, California · NCT07441395

• GX-03 topical treatment for adults with moderate to severe eczema

  This study will test whether applying GX-03, a topical emollient, twice daily for 8 weeks reduces eczema severity and itch in adults with moderate to severe atopic dermatitis compared with a petrolatum-based vehicle.

  Recruiting Phase 2/3 Turn Therapeutics · Irving, Texas · NCT07355075

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.